AI

One Drop Delivers Novel AI-Powered Solution For Cardiovascular Disease Prevention

One Drop | October 28, 2021

One Drop, a leader in precision health solutions for people living with chronic conditions worldwide, today announced the release of a digital, AI-enabled cardiovascular disease (CVD) prevention module. The new CVD prevention module is the first co-developed digital product to emerge from the collaboration between One Drop and Bayer in support of One Drop's expansion into a wide range of therapeutic areas.According to the World Health Organization, at least 80% of heart disease, stroke, and type 2 diabetes are preventable. Yet, cardiovascular disease continues to be the leading cause of death in the U.S. One Drop's CVD prevention module provides members with a personalized digital health program that combines clinical best practices with the latest in technology and predictive analytics to reduce CVD risk.

"The new CVD prevention module comes from combining our respective expertise to jointly bridge the gap between healthcare and technology," said Jeanne Kehren, CIO and head of digital and commercial innovation, Bayer Pharmaceuticals. "This launch is an important milestone in our joint endeavor with One Drop to make integrated care a transformative solution for the patients and a key player in the healthcare industry."

The digital-first approach to CVD prevention provides a holistic set of digital tools and coaching placing One Drop members on a healthier path by personalizing care, gathering data, and providing actionable insights, all in a user-friendly mobile app. The program seeks to reduce the broader burden of disease for those at risk while lowering costs for employers and health plans.

"By removing barriers to access to care and critical health information, One Drop instills confidence in our members, equipping them with the tools needed to make intelligent decisions, improve outcomes, and reach their full potential. The life-altering potential of our cardiovascular disease prevention module would not have been possible without the support and deep expertise from our strategic partner, Bayer. The CVD prevention module is one of many outputs to come, thanks to our productive partnership that will help countless people improve their lives."

Rachel Yap Martens, EVP of commercial solutions and corporate strategy at One Drop

The One Drop CVD prevention module offers several ways to optimize an individual's health, including:

  • Connected medical devices to help lower heart disease risk: Best-in-class medical devices from Withings capture blood pressure and weight automatically tracked in the One Drop app alongside food, medications, physical activity, glucose, and A1C from thousands of other integrations.
  • Heart-healthy habit-building backed by science: The program combines behavioral science principles, data science, and customized educational content to guide members towards positive habits in weight management, physical activity, and diet for a heart-healthy life.
  • Simplified food logging linked to health trends: A leading-edge food logging experience makes it easier for members to stay on track while also allowing them to observe and react to trends over time. Includes sodium and fiber tracking.
  • One-on-one health coaching by registered nurses (RNs): Direct access to health management professionals specializing in CVD for personalized support and regular progress check-ins.
  • Biometric predictions and insights, powered by artificial intelligence: The CE-marked analysis engines behind glucose forecasts and blood pressure insights are powered by One Drop's proprietary machine learning algorithms and more than 30 billion health data points from millions of members worldwide. Blood pressure insights help members at risk for CVD understand how their blood pressure is trending and offer tactical recommendations and support in real-time.

The CVD prevention module is available to new and renewing employer customers via One Drop's multi-condition employer program. One Drop will offer consumers a health-focused program in Fall 2021, available in the award-winning One Drop app (iOS and Android).

About One Drop
One Drop is a precision health company at the nexus of personal diagnostics, artificial intelligence, and telehealth. Powered by machine learning algorithms and a wealth of real-time data, the digital platform combines predictive insights, a behavior change program, and the human touch of coaching, filling in the gaps between doctor's visits and simplifying daily decision-making. The goal: empower everyone to take proactive action for better health outcomes, peak performance, and a more fulfilling life.

Spotlight

Each day, more than 32,000 caregivers across Aurora Health Care help people live well.Aurora Cancer Care is the leading provider of cancer care in Wisconsin. 1 of every 4 patients treated for cancer in the state receive care at an Aurora facility.This is a day in the life of Aurora Cancer Care and Dr. Papenfuss.


Other News
HEALTH TECHNOLOGY

Philips and IJsselland Hospital sign long-term technology partnership

Royal Philips | December 24, 2021

Royal Philips, a global leader in health technology, today announced it has signed a 12-year strategic partnership with IJsselland Hospital (Capelle aan den Ijssel, The Netherlands). As the hospital’s strategic technology partner, Philips will target improved care for patients and care providers at IJsselland Hospital and in the surrounding region. The collaboration will focus on innovation, digitalization and optimization, and includes the purchase of patient monitoring and radiology solutions including CT and MRI systems. Home monitoring collaboration expanded In addition to the new strategic partnership, Philips and IJsselland Hospital plan to expand their existing home monitoring partnership for patients with heart failure and COPD. Philips will provide clinical and patient decision support software which enables implementation of remote health and care programs and facilitates collaboration between different healthcare providers. “Technological developments in healthcare are currently moving very fast,” said Albert van Wijk, Chairman of IJsselland Hospital’s Board of Directors. “As a regional hospital, we want to keep up with these developments to provide the best care for our patients. We have chosen Philips as a technology partner to jointly develop the hospital of the future. This will be good for our patients and our healthcare professionals. Moreover, Philips’ vision fits well with our strategy.” “Over the past year, we have worked with IJsselland Hospital to convert their strategy and challenges into a partnership. I am very proud of this partnership, in which we don’t focus solely on technology but look more broadly at the challenges the hospital faces. A great deal of attention is paid to innovation, which is why we are starting a joint fund for innovation and optimization. We also want to work explicitly on optimizing care processes, so that the hospital can work smarter and save costs.” Léon Kempeneers, Health Systems, Philips Benelux About Royal Philips Royal Philipsis a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries.

Read More

HEALTH TECHNOLOGY

The GIANT Health Event 2021. Early bird tickets on sale now

GIANT Health | October 13, 2021

Europe's greatest festival of Health Tech Innovation | 30th Nov - 1st Dec 2021 Join us at GIANT this year and immerse yourself in Europe's greatest festival of healthcare innovation. Find inspiration from global leading innovators, and discover the advances in technology that are revolutionizing healthcare provision. GIANT 2021 is set to be our biggest event yet so don't miss out. GIANT Health event is an invaluable, cost-effective global hybrid event. Combining both a real-world physical trade show and multiple conferences in central London, as well as a sophisticated and engaging virtual event based on GIANT Health’s proprietary Virtual Event Platform. Learn more about Digital Therapeutics.Would you like to network with 1000s and 1000s of Europe's leading healthcare and technology innovators, hospital leaders, health-sector investors, and entrepreneurs?Over 400 speakers will convene in 15+ conference at the massive GIANT Health Event, 30 November - 1 December, 2021. Come join us in person or remotely.Early Bird tickets are now available. CLAIM YOUR TICKET HERE A special promotional code which allows to save up to 25% on top is available for our subscribers: MEDIA25 See you there! Media contact: GIANT Health Events Ltd Olga Nosova +44 20 8144 9779 Olga@GIANT.health

Read More

HEALTH TECHNOLOGY

Microbot Medical Announces Strategic Collaboration with Stryker Corporation to Develop the LIBERTY® Robotic System for Neurovascular Applications

Microbot Medical | December 28, 2021

Microbot Medical Inc.announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company. The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain neurovascular procedures. “We have already ensured that the LIBERTY Robotic System has a strong and sustainable competitive advantage, and the collaboration with Stryker will allow us to further expand in the neurovascular space. I believe the similarities in our innovation culture, as well as our complementary core capabilities, will allow us to establish a truly differentiated solution that will benefit all stakeholders and accelerate our goal of changing the way robotic surgery is viewed and adopted.” Harel Gadot, Chairman, CEO and President of Microbot Medical The company will continue to develop the LIBERTY Robotic System independently for use in peripheral and coronary procedures. The animal feasibility studies to date support the company’s assertion that it will potentially allow physicians to safely and efficiently conduct remote catheter-based vascular procedures, and reduce the risk for radiation exposure, physical strain on the user and Hospital Acquired Infections (HAIs), without the need for cumbersome and expensive capital equipment. About Microbot Medical Microbot Medical Inc.is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP). Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies.

Read More

FUTURE OF HEALTHCARE

Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products

Endonovo Therapeutics, Inc. | April 26, 2022

Endonovo Therapeutics, Inc. announced an agreement with NAMSA – a leading Global Contract Research Organization and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF product SofPulse®. “Engaging NAMSA as strategy advisors to develop and apply proven medical device reimbursement strategies is a huge advantage for Endonovo and our shareholders, according to Endonovo CEO Alan Collier. “NAMSA is a proven medical device development partner with relevant therapeutic know-how that is critical when seeking acceleration of reimbursement efforts and commercialization objectives,” he pointed out. NAMSA was founded in 1967 as a scientific research company and later transitioned into a Global CRO and Medtech (Medical Technologies) reimbursement specialist. Today, it has 1,000 strategic associates who provide Medtech reimbursement advisory expertise to more than 300 clients in 15 global regions. NAMSA offers a full continuum of reimbursement services for medical technologies. Their reimbursement consultants provide: payer relations, medical policy research, coverage advocacy, Healthcare Common Procedure Coding System Current Procedural Terminology code analysis/applications and health economic analysis. “Our team strives to bring impactful products like the Endonovo SofPulse into higher adoption. With this technology, and its favorable economics, there are multiple opportunities ahead for serving populations in need. We will work together with the Endonovo team to improve market access for this novel device in the very near term.”, Joseph Sierra, Director, Reimbursement Consulting, North America, NAMSA NAMSA provides strategic guidance and tactical support to fast-track medical device commercialization and to make an immediate impact on patient healthcare worldwide. NAMSA’s services have grown to include regulatory, reimbursement and quality consulting as well as clinical research. These additions have helped NAMSA to become the pre-eminent 100% medical device-focused Global CRO that offers proven strategic solutions throughout the full development continuum. NAMSA is the only US FDA ASCA accredited medical device biocompatibility laboratory in the world. This allows medical device sponsors to fast-track commercialization efforts, while achieving time and cost efficiencies in every major market of the world. Collier stated: “We are fortunate to be working directly with Joseph Sierra, at NAMSA. With over 10 years of reimbursement experience, and his proven track-record in developing successful medical device reimbursement strategies is exemplary and will be helpful in developing the path toward reimbursement for our main product SofPulse®. Joseph is an adjunct instructor at USC Masters of Health Administration Program, and his prior professional work includes successful stints with NeoFect USA and Medtronic Ltd. where he demonstrated a record of success leading roles in reimbursement programs, analysis, and strategies for their medical devices.” NAMSA’s reimbursement expertise and track-record in the introduction and adoption of medical devices into multiple medical specialties includes: orthopedics, cardiovascular surgery, general surgery, plastic surgery, neurology, robotic surgery and wound care. Collaborating with NAMSA on global reimbursement allows Endonovo to explore reimbursement for the U.S. medical markets as well as the European Union market adoption through SofPulse® medical CE Mark. Additional target markets would be Taiwan and other Asian countries. About Endonovo Therapeutics Inc. Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system disorders, including traumatic brain injury, acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema. It also has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease, non-alcoholic steatohepatitis cardiovascular and peripheral artery disease and ischemic stroke. The Company's noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Read More

Spotlight

Each day, more than 32,000 caregivers across Aurora Health Care help people live well.Aurora Cancer Care is the leading provider of cancer care in Wisconsin. 1 of every 4 patients treated for cancer in the state receive care at an Aurora facility.This is a day in the life of Aurora Cancer Care and Dr. Papenfuss.

Resources